New York Mortgage Trust, Inc. (NYMT)
NASDAQ: NYMT · Real-Time Price · USD
6.58
+0.25 (3.95%)
At close: Aug 1, 2025, 4:00 PM
6.63
+0.05 (0.76%)
After-hours: Aug 1, 2025, 4:20 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $7.81, which forecasts a 18.69% increase in the stock price over the next year. The lowest target is $6.75 and the highest is $9.00.
Price Target: $7.81 (+18.69%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $6.5 → $6.75 | Hold | Maintains | $6.5 → $6.75 | +2.58% | Jul 10, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $8 → $9 | Strong Buy | Maintains | $8 → $9 | +36.78% | May 2, 2025 |
| Jones Trading | Jones Trading | Strong Buy Maintains $7.5 | Strong Buy | Maintains | $7.5 | +13.98% | May 2, 2025 |
| Jones Trading | Jones Trading | Strong Buy Maintains $7.5 | Strong Buy | Maintains | $7.5 | +13.98% | Feb 24, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $11 → $8 | Strong Buy | Maintains | $11 → $8 | +21.58% | Jan 7, 2025 |
Financial Forecast
Revenue This Year
152.16M
from 143.24M
Increased by 6.23%
Revenue Next Year
170.55M
from 152.16M
Increased by 12.09%
EPS This Year
1.06
from -1.14
EPS Next Year
0.88
from 1.06
Decreased by -16.87%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 179.9M | 207.1M | 202.2M |
| Avg | 152.2M | 170.6M | 196.5M |
| Low | 132.3M | 141.4M | 188.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 25.6% | 36.1% | 18.6% |
| Avg | 6.2% | 12.1% | 15.2% |
| Low | -7.7% | -7.1% | 10.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.37 | 0.99 | 1.08 |
| Avg | 1.06 | 0.88 | 1.05 |
| Low | 0.84 | 0.76 | 1.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | -7.2% | 22.3% |
| Avg | - | -16.9% | 18.8% |
| Low | - | -28.1% | 14.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.